The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects

INTRODUCTION: Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being investigated for acute treatment of migraine. Early clinical data suggested greater than dose proportional increases in exposure following oral administration. The aim of the present studies wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tae H, Blanchard, Rebecca L, Palcza, John, Martucci, Ashley, Miller-Stein, Cynthia M, Gutierrez, Maria, Panebianco, Deborah, Rippley, Ronda K, Lines, Christopher, Murphy, M Gail
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015066/
https://www.ncbi.nlm.nih.gov/pubmed/21221171
http://dx.doi.org/10.1111/j.1753-5174.2010.00031.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015066/
https://www.ncbi.nlm.nih.gov/pubmed/21221171
http://dx.doi.org/10.1111/j.1753-5174.2010.00031.x

Ejemplares similares